Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study to Evaluate the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

NCT06917313 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT06917313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06917313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study to Evaluate the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy
Lead sponsor
Yale University
Phase
Phase 2
Overall status
Recruiting
Start date
December 5, 2025
Completion date
March 31, 2028
Enrollment
92 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer early stage breast cancer (stage 1-3)